Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Content from MarketBeat Pfizer Adds to Its Big Bet on Weight Loss DrugsWritten by Jordan Chussler. Published 12/16/2025. 
Key Points - The health care sector has led the S&P 500 over the three months, but Pfizer has lagged of late, slipping 5% since the start of October.
- As the Big Pharma company continues to struggle to replace COVID-19 vaccine revenue, it is heavily learning into the semaglutide and GLP-1 weight loss drug trend.
- Last week, the company signed a $2.1 billion licensing agreement with a Chinese pharma company to develop its early-stage weight loss pill.
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that rally has not included all of the Big Pharma mainstays. Pfizer (NYSE: PFE), the maker of Chantix, Eliquis and Paxlovid, has seen its shares slide 5% since the start of October. By comparison, other mega-cap pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), Regeneron Pharmaceuticals (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) are up nearly 14%, 24%, and 25%, respectively, over the same time frame. Why Is Nobody Talking About What Just Happened at Mar-a-Lago?
He served on one of Trump's top advisory boards... and he's been a personal friend of the President for years... But what he just revealed at Mar-a-Lago about President Trump has made some people uncomfortable. The mainstream won't touch this story. But if you're an American patriot looking to build wealth, you need to hear what he's saying. Get the name and ticker of his #1 "Mandatory Payout" stock to buy now, FREE And despite Pfizer making headlines on Nov. 13 after acquiring obesity biotech Metsera in a $10 billion deal, the stock has only managed a 0.23% gain since then. The nearly 177-year-old biopharma company is once again looking to expand its role in the weight-loss drug market, with management and shareholders hoping that doing so can help it recover revenue lost as demand for mRNA COVID-19 vaccines waned. Pfizer Looks to Gain Market Share After Deal With YaoPharma On Tuesday, Dec. 9, Pfizer struck a $2.1 billion licensing deal with China's YaoPharma to develop a GLP‑1 weight-loss pill that is in early-stage development. The drug is intended to work similarly to Wegovy, Novo Nordisk's game-changing weight-loss injection. News of a yet-to-be-approved pill may not move the stock in the short term, but it underscores Pfizer's commitment and momentum in the obesity-treatment market. Under the agreement, Pfizer will pay a $150 million upfront fee to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, which has an $8.4 billion market cap. Pfizer could also pay up to $1.94 billion in milestone payments if the drug advances toward approval, plus royalties on sales if it reaches the market. Those milestone payments are contingent on YaoPharma successfully advancing the pill through early clinical trials, after which Pfizer will take control of later-stage development. Pfizer also plans combination studies—currently in mid-stage development—that will pair the Chinese pharma's pill with Pfizer's own GIP-targeting therapy, mirroring the dual GLP‑1/GIP approach Eli Lilly has used with Zepbound and Mounjaro. Positioning for the Future of the Weight-Loss Market The deal highlights how aggressively Pfizer's executives are pursuing a larger, long-term position in the GLP‑1 and broader obesity-treatment market. Over the past month, Pfizer has shown it is willing to invest roughly $10.1 billion to pursue that strategy as it targets a rapidly growing industry. Forecasts from market analysis firm Grand View Research project the GLP‑1 weight-loss drug market to grow at a compound annual growth rate (CAGR) of 18.54% from 2025 to 2030, rising from under $14 billion this year to an estimated $48.84 billion by 2030. Grand View Research found North America accounts for the largest revenue share, more than 75% of the GLP‑1 agonists market. While other obesity interventions exist, including lifestyle changes and bariatric surgery, GLP‑1 drugs remain the preferred option among many physicians and patients. Patient Investors Can Enjoy PFE's Sizable Dividend Shareholders are betting Pfizer's push into weight-loss treatments will pay off after the stock has punished loyal investors with a loss of more than 31% over the past five years. Much of that decline stems from reduced COVID-vaccine sales, which drove revenue growth from more than 95% at the end of 2021 to a decline of over 41% by the end of 2023. Last year, Pfizer rebounded modestly, posting nearly a 7% increase in revenue. The stock's dividend has also helped cushion investor concerns: Pfizer remains a strong dividend payer with a current yield of 6.65%—$1.72 per share annually. That payout has increased for 16 consecutive years, making the stock attractive to income investors despite a 100% payout ratio that raises some questions. For investors who prioritize income and remain bullish on the near- and mid-term prospects for prescription weight-loss drugs, Pfizer can serve as a speculative way to participate in the GLP‑1 industry while collecting yield. Growth-focused investors, however, may find it hard to tolerate another year of tepid performance. Analysts' average 12-month price target implies a little more than 10% upside from the current price and carries a consensus Hold rating. Meanwhile, short interest has been steadily rising as Wall Street's bears increase their exposure. Currently, about $3.58 billion of the float is shorted—nearly 84% more than PFE's short position at the end of January 2025.
| 
